Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021

NCT05382182 | Unknown

• 1 other identifier: Soh-Med-22-05-03
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Worldwide, prostate cancer is the most commonly diagnosed male cancer and the fourth leading cause of cancer death in men. Risk stratification is according to cancer stage, Gleason score, and PSA level . Definitive treatment of localized disease ( low and favorable intermediate risk) includes watchful waiting , active surveillance , radiation therapy , radical prostatectomy and cryotherapy .Primary treatment of unfavorable intermediate risk , high risk localized disease and locally advanced prostate cancer , includes both radical prostatectomy (RP) and EBRT + long-term androgen deprivation therapy (ADT) .Treatment options of metastatic prostate cancer include pain medications, bisphosphonates, hormonal treatment, chemotherapy, radiotherapy, immunotherapy, focused radiation, and other targeted therapies .

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (3)

• overall survival

  Overall survival defined as the time from the date of diagnosis to the last date seen .

  6 months

• progression free survival

  Progression-free survival defined as the length of time during and after the treatment of cancer that a patient lives with the disease but it does not get worse.

  6 months

• disease free survival

  Disease free survival defined as the time from the end of treatment to the date of first relapse .

  6 months

Interventions

androgen deprivation therapy DRUG

outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse

external beam radiotherapy RADIATION

outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse

Eligibility Criteria

• Age: 18 Years+
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

prostate cancer patients

You may qualify if:

• Patients at age of 18 years old and above.
• All stages and grades of prostate cancer.
• Epithelial types of prostate cancer.

You may not qualify if:

• Age below 18 years old.
• Presence of other malignancies.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University Hospital

Sohag, Egypt

Location

Related Publications (4)

• Costello LC, Franklin RB. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys. 2016 Dec 1;611:100-112. doi: 10.1016/j.abb.2016.04.014. Epub 2016 Apr 27.

  PMID: 27132038 BACKGROUND

• Herden J, Heidenreich A, Weissbach L. [TNM-Classification of localized prostate cancer : The clinical T-category does not correspond to the required demands]. Urologe A. 2016 Dec;55(12):1564-1572. doi: 10.1007/s00120-016-0264-5. German.

  PMID: 27830286 BACKGROUND

• Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouviere O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4.

  PMID: 32146018 BACKGROUND

• Verma S, Choyke PL, Eberhardt SC, Oto A, Tempany CM, Turkbey B, Rosenkrantz AB. The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer. Radiology. 2017 Nov;285(2):343-356. doi: 10.1148/radiol.2017161684.

  PMID: 29045233 BACKGROUND

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Androgen Antagonists

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Central Study Contacts

Aya A Sayed, resident

CONTACT

01023423815; ayaahmed@med.sohag.edu.eg

Ali M Ali, assisstant professor

CONTACT

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident doctor at oncology department at faculty of medicine sohag university hospital

Study Record Dates

• First Submitted: May 15, 2022
• First Posted: May 19, 2022
• Study Start: June 1, 2022
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: May 19, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will share

Locations

EG (1)